Hepatitis Therapeutics Market Size, Share, Regional Growth, 2026-2034

Market Overview

According to fortune business insights, The global hepatitis therapeutics market size was valued at USD 4.04 billion in 2024. The market is projected to grow from USD 4.06 billion in 2025 to USD 8.40 billion by 2032, exhibiting a CAGR of 10.93% during the forecast period. North America dominated the hepatitis therapeutics market with a market share of 50.0% in 2024.The analysis shows that top companies are investing more in hepatitis therapeutics because of the rising prevalence of hepatitis indications and increasing diagnostic capabilities. For example, in September 2025, AusperBio Therapeutics, Inc. collaborated with Ausper Biopharma Co., Ltd. to advance targeted therapies for chronic hepatitis B with a USD 63.0 million investment. This trend indicates a strong demand for hepatitis therapeutics worldwide.

Major Players Profiled in the Market Report:

• Bristol-Myers Squibb Company (U.S.)• Zydus Group (U.S.)• GSK plc. (U.K.)• AbbVie Inc. (U.S.)• Gilead Sciences, Inc. (U.S.)• Merck & Co., Inc. (U.S.)• F Hoffmann-La Roche Ltd (Switzerland)• Atea Pharmaceuticals, Inc. (U.S.)• Teva Pharmaceutical Industries Ltd.(Israel)

SegmentsIncreasing Prevalence of Hepatitis B to Propel Segmental GrowthBased on indication, the market is divided into hepatitis B, hepatitis C, hepatitis D, and others. The hepatitis B segment holds the largest market share and dominates the market owing to the high global prevalence of chronic Hepatitis B infection, which requires long-term antiviral therapy to prevent liver damage.Ease of Administration to Drive Oral Segment ExpansionBy route of administration, the market is categorized into oral and parenteral. The oral segment is leading the market as there is a high demand for orally administered drugs due to their ease of administration and better patient compliance compared with parenteral routes.Hospital Pharmacies to Dominate the Market Due to Their Critical Role in Patient ManagementBased on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies & others. The hospital pharmacies segment holds the largest market share owing to the dependence of hepatitis patients on hospital-based treatment for diagnosis, monitoring, and management of advanced liver disease.

Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Source: https://www.fortunebusinessinsights.com/hepatitis-therapeutics-market-114700

Report CoverageThe report offers:• Major growth drivers, restraining factors, opportunities, and potential challenges for the market.• Comprehensive insights into regional developments.• List of major industry players.• Key strategies adopted by the market players.• The latest industry developments include product launches, partnerships, mergers, and acquisitions.

Drivers & RestraintsIncreasing Disease Burden to Propel Market GrowthThe increasing prevalence of hepatitis infections globally is a major driver, with a surge in chronic hepatitis B and C cases intensifying the need for effective antiviral therapies. As the diagnosed patient pool expands, so does the demand for therapeutics, boosting the hepatitis therapeutics market growth.However, adverse effects associated with some hepatitis therapeutics, such as fatigue, anemia, and gastrointestinal discomfort, may hamper market growth. These side effects can negatively affect patient compliance and limit the long-term expansion and revenue potential of certain treatments.

Regional InsightsHigh Diagnostic Rates and R&D Investment Propels Market Growth in North AmericaNorth America holds the dominant hepatitis therapeutics market share and is projected to experience growth during the forecast period. The region’s growth is attributed to high diagnostic rates, a growing prevalence of liver disorders, robust healthcare infrastructure, and substantial investment in research, development, and clinical trials.Europe is one of the fastest-growing regions in the market. The growth is attributed to widespread government screening activities, increasing national reimbursement schemes, and a strong focus on improving access to critical treatments.

Hepatitis Therapeutics Market Future Growth:The hepatitis therapeutics market is experiencing robust growth, fueled by an increasing disease burden, rising government support for elimination programs, and a significant shift toward precision medicine. Today's market is increasingly focused on developing innovative and tailored antiviral therapies that improve efficacy and reduce adverse effects. The development of personalized antiviral drugs, supported by advancements in genomic sequencing and biomarker identification, is a key growth driver. Additionally, there is a growing trend of strategic collaborations and investments aimed at achieving a functional cure for chronic hepatitis, particularly hepatitis B. While North America continues to dominate, regions like Asia Pacific and Europe are seeing a surge in demand, driven by large-scale screening initiatives and improving healthcare access.

Competitive LandscapeGrowing Focus on Clinical Trials and Strategic Collaborations to Propel Market GrowthThe market features prominent players like GSK plc., Gilead Sciences, Inc., and Merck & Co., Inc. These leading companies are accelerating growth through strategic initiatives such as collaborations to advance research and extensive ongoing clinical trials for new therapies. Their proactive approach to developing innovative candidates and expanding treatment pipelines in response to the unmet clinical demand continues to fuel the market’s momentum.

Key Industry Development• June 2025: AstriVax Therapeutics NV initiated clinical development with AVX70371 for the treatment of chronic hepatitis B virus (HBV) infection.• March 2025: Brii Biosciences Limited presented end-of-treatment (EOT) data from its ongoing Phase 2 ENSURE study at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025).• March 2025: Vir Biotechnology, Inc. completed enrollment for ECLIPSE 1, a Phase 3 trial evaluating a combination therapy for patients with chronic hepatitis delta (CHD).